Fluoroquinolone-associated dysglycemias: A tale of two toxicities

Pharmacotherapy

Volumn 25, Issue 10 I, 2005, Pages 1291-1295

  Owens Jr , Robert C ^a,b  

^a MAINE MEDICAL CENTER   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Dysglycemia; Fluoroquinolones; Hyperglycemia; Hypoglycemia

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; GATIFLOXACIN; GEMIFLOXACIN; GLIBENCLAMIDE; GLUCOSE; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONYLUREA DERIVATIVE;

DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; POSTMARKETING SURVEILLANCE; RISK FACTOR;

ANTI-INFECTIVE AGENTS; BLOOD GLUCOSE; CLINICAL TRIALS; FLUOROQUINOLONES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; PRODUCT SURVEILLANCE, POSTMARKETING; RISK FACTORS;

EID: 26044475604     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.10.1291     Document Type: Editorial

References (31)

1. Mohr JF, McKinnon PS, Peymann PJ, Kenton I, Septimus E, Okhuysen PC. A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Pharmacotherapy 2005;25:1303-9.
2. Graumlich JF, Habis S, Avelino RR, et al. Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested, case-control study. Pharmacotherapy 2005;25:1296-302.
3. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287: 2215-20.
4. Shilo S, Berezovsky S, Friedlander Y, Sonnenblick M. Hypoglycemia in hospitalized nondiabetic older patients. J Am Geriatr Soc 1998;46:978-82.
5. Kagansky N, Levy S, Rimon E, et al. Hypoglycemia as a predictor of mortality in hospitalized elderly patients. Arch Intern Med 2003;163:1825-9.
6. Chelliah A, Burge MR. Hypoglycemia in elderly patients with diabetes mellitus: causes and strategies for prevention. Drugs Aging 2004;21:511-30.
7. Mittmann N, Knowles SR, Gomez M, Fish JS, Cartotto R, Shear NH. Evaluation of the extent of under-reporting of serious adverse drug reactions: the case of toxic epidermal necrolysis. Drug Safety 2004;27:477-87.
8. Grasela D, LaCreta F, Kollia G, et al. Lack of effect of multiple-dose gatifloxacin on oral glucose tolerance, glucose and insulin homeostasis, and glyburide pharmacokinetics in patients with type II non-insulin-dependent diabetes mellitus [abstr]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA, September 26-29, 1999. Washington, DC: American Society for Microbiology, 1999.
9. Gajjar DA, LaCreta FP, Kollia GD, et al. Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise. Pharmacotherapy 2000;20(6 suppl 2):S76-86.
10. Stass H, Kubitza D. Profile of moxifloxacin drug interactions. Clin Infect Dis 2001;32(suppl 1)547-50.
11. U.S. Food and Drug Administration. New drug applications. Rates of hypoglycemia. Available from http://www.fda.gov/cder/approval/index.htm. Accessed January 10, 2004.
12. Genesoft Pharmaceuticals. Factive (gemifloxacin) package insert. South San Francisco, CA; 2003.
13. Bayer Pharmaceuticals. Cipro (ciprofloxacin) package insert. West Haven, CT; 2003.
14. Bristol-Myers Squibb. Tequin (gatifloxacin) package insert. Princeton, NJ; 2002.
15. Ortho-McNeil Pharmaceuticals. Levaquin (levofloxacin) package insert. Raritan, NJ; 2003.
16. Bayer Pharmaceuticals. Avelox (moxifloxacin) package insert. West Haven, CT; 2003.
17. Shailer PA, Randinitis E, Rausch G, Sedman A, Vassos A. Effect of clinafloxacin on serum insulin and glucose levels in healthy subjects [abstr]. Clin Pharm Ther 1997;61:148.
18. Welling L, Burke CL. Safety of clinafloxacin, a new fluoroquinolone antibiotic [abstr]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA, September 26-29, 1999. Washington, DC: American Society for Microbiology, 1999.
19. Owens RC Jr. QT prolongation with antimicrobial agents: understanding the significance. Drugs 2004;64:1091-124.
20. Shatter D, Singer S, Korvick J, Honig P. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration adverse event reporting system. Clin Infect Dis 2002;35:197-200.
21. Owens RC Jr, Ambrose PG. Torsades de pointes associated with fluoroquinolones. Pharmacotherapy 2002;22:663-72.
22. Nicholson SC, High KP, Gothelf S, et al. Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly. Diagn Microbiol Infect Dis 2002;44:109-16.
23. Coblio NA, Mowrey K, McCright P, Means H, McCormick MT. Use of a data warehouse to examine the effect of fluoroquinolones on glucose metabolism. Am J Health-Syst Pharm 2004;61:2545-8.
24. Rosati B, Rocchetti M, Zaza A, Wanke E. Sulfonylureas blockade of neural and cardiac HERG channels. FEBS Lett 1998;440:125-30.
25. Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005;40(suppl 7):S456-69.
26. Ashcroft FM, Gribble FM. ATP-sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia 1999;42:903-19.
27. Maeda N, Tamagawa T, Niki I, et al. Increase in insulin release from rat pancreatic islets by quinolone antibiotics. Br J Pharmacol 1996;117:372-6.
28. Saraya A, Yokokura M, Gonoi T, Seino S. Effects of fluoroquinolones on insulin secretion and β-cell ATP-sensitive K+ channels. Eur J Pharmacol 2004;497:111-17.
29. Biggs WS. Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients. J Am Board Fam Pract 2003;16:455-7.
30. Abramowicz M, ed. Hypoglycemia and hyperglycemia with fluoroquinolones. Med Lett Drugs Ther 2003;45:64-5.
31. Ambrose PG, Bhavnani SM, Cirrincione BB, Piedmonte M, Grasela TH. Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. J Antimicrob Chemother 2003;52:435-40.